Skip To Content

Study ID: ECOG-ACRIN E4512

Title:

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Lung
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.